Advances on Cellular Clonotypic Immunity in Amyotrophic Lateral Sclerosis
Open Access
- 20 October 2022
- journal article
- review article
- Published by MDPI AG in Brain Sciences
- Vol. 12 (10) , 1412
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease, characterized by the progressive degeneration of the upper and lower motor neurons in the cortex and spinal cord. Although the pathogenesis of ALS remains unclear, evidence concerning the role of the clonotypic immune system is growing. Adaptive immunity cells often appear changed in number, or in terms of their activation profiles, both peripherally and centrally; however, their role in ALS appears conflictive. Data from human and animal model studies, which are currently reported in the literature, show that each subset of lymphocytes and their mediators may mediate a protective or toxic mechanism in ALS, affecting both its progression and risk of death. In the present review, an attempt is made to shed light on the actual role of cellular clonotypic immunity in ALS by integrating recent clinical studies and experimental observations.Keywords
All Related Versions
This publication has 63 references indexed in Scilit:
- Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survivalEMBO Molecular Medicine, 2012
- Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2011
- FUS‐immunoreactive inclusions are a common feature in sporadic and non‐SOD1 familial amyotrophic lateral sclerosisAnnals of Neurology, 2010
- Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation?Acta Neurologica Scandinavica, 2010
- Overview of the immune responseJournal of Allergy and Clinical Immunology, 2010
- IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patientsJournal of Neuroinflammation, 2010
- Thymic involution, a co‐morbidity factor in amyotrophic lateral sclerosisJournal of Cellular and Molecular Medicine, 2009
- IgG subclass deficiency in amyotrophic lateral sclerosisActa Neurologica Scandinavica, 2009
- Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trialAmyotrophic Lateral Sclerosis, 2009
- T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALSProceedings of the National Academy of Sciences, 2008